Just a few neoantigens may be enough for T cells to control

$ 10.00

4.8 (140) In stock

In a phase II clinical trial, 29 patients with metastatic castration-resistant prostate cancer were treated with ipilimumab after tumor resection. Median radiographic PFS was 3 months, median clinical PFS was 2 months, and median OS was 24 months. Best ORR was stable disease in 37% of patients. In the “favorable” cohort (PFS>6 months, median OS of 45 months), pretreatment tumors had increased CD8+ T cell density and IFNγ response gene signature compared with the “unfavorable” cohort (PFS<6 months, median OS of 5 months), while TMB was similar between cohorts. In post-treatment PBMCs, CD8+ T cell responses to PSMA, PAP, and/or neoantigens were found in 4 patients, all of which were in the favorable cohort.

Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges, Biomarker Research

Frontiers The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines

The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells, Molecular Cancer

Recognition of tumor neoantigens by CD8 + T cells. receptors on CD8 + T

When neoantigen expression is low, the T cells won't go

PDF] Neoantigens and their potential applications in tumor immunotherapy

Neoantigens and current immune checkpoint inhibitors. (A) Tumor

Developing neoantigen-targeted T cell–based treatments for solid tumors

What are Cancer Neoantigens? The Link Between Neoantigens and Immunotherapy – What's New in GU?